SSRI Use in Pregnancy and Congenital Heart Defects: A Meta-Analysis of Population Based Cohort Studies by Kowalik, Elizabeth A
University of Rhode Island
DigitalCommons@URI
Senior Honors Projects Honors Program at the University of Rhode Island
2016
SSRI Use in Pregnancy and Congenital Heart
Defects: A Meta-Analysis of Population Based
Cohort Studies
Elizabeth A. Kowalik
University of Rhode Island, ekowalik@my.uri.edu
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 License.
Follow this and additional works at: http://digitalcommons.uri.edu/srhonorsprog
Part of the Pharmacy and Pharmaceutical Sciences Commons
This Article is brought to you for free and open access by the Honors Program at the University of Rhode Island at DigitalCommons@URI. It has been
accepted for inclusion in Senior Honors Projects by an authorized administrator of DigitalCommons@URI. For more information, please contact
digitalcommons@etal.uri.edu.
Recommended Citation
Kowalik, Elizabeth A., "SSRI Use in Pregnancy and Congenital Heart Defects: A Meta-Analysis of Population Based Cohort Studies"
(2016). Senior Honors Projects. Paper 486.
http://digitalcommons.uri.edu/srhonorsprog/486http://digitalcommons.uri.edu/srhonorsprog/486
SSRI Use in Pregnancy and Congenital Heart Defects: A Meta-Analysis of Population-Based Cohort 
Studies  
Elizabeth Kowalik  
Sponsor: Kristina Ward  
 
 The American College of Obstetricians and Gynecologists (ACOG) estimate that 10-23% of 
pregnant women in the United States face depression at some point during their pregnancy.1 However, 
no clear recommendations regarding the treatment of depression in pregnancy are available. The 
American Psychiatric Association (APA) and ACOG both agree that antidepressant medication safety is 
uncertain. Antidepressants are commonly used during pregnancy without clear evidence of their safety. 
The Centers for Disease Control and Prevention (CDC) found that 298 (4.5%) of 6582 women in 10 states 
between the years of 1998 and 2005 had taken an antidepressant at some time during a pregnancy or 
up to three months before pregnancy. Of the women, 250 (3.8%) used a selective serotonin reuptake 
inhibitor (SSRI) making them the most commonly used type of antidepressant in pregnancy.2 A major 
concern with SSRI use during pregnancy is the potential risk for congenital malformations, including 
congenital heart defects (CHD), which are the most common type of birth defect in the United States. 
The purpose of the meta-analysis was to determine if risk of CHD is associated with the use of SSRIs 
during pregnancy.  
 The biomedical literature was searched extensively.  The systematic search involved three 
databases: PubMed, EMBASE, and Cochrane Database. Over one-thousand articles were reviewed 
following the searches. Studies were narrowed based on a variety of inclusion and exclusion criteria. 
Following exclusion, eight studies were selected for further analysis. The outcome measured in this 
analysis was the presence of CHDs in children. The analysis was conducted using R studio with the 
metafor package. A random effects model was utilized and odds ratio and confidence intervals 
calculated for each study along with an overall pooled risk. The studies included in the meta-analysis 
were also evaluated for heterogeneity using I2and Cochran’s Q.  
The results of the analysis showed a significant association between the use of SSRIs in 
pregnancy and the development of CHD in children. The overall result was associated with significant 
heterogeneity. Our meta-analysis shows that risk of CHD may be increased when SSRIs are used during 
pregnancy. The potential risk of CHD should be considered in the risk-benefit discussion when initiating 
SSRI therapy in pregnant women or women of child-bearing age. However, the meta-analysis results 
show that use of SSRIs in pregnancy is not benign. While the overall increased risk of CHDs is low, risk 
should be considered by providers and discussed with women before initiating therapy.  
 I learned a lot about the research process throughout this project and it has been extremely 
rewarding. I gained a new appreciation for meta-analyses. The literature review process was very 
extensive and time consuming, but now I feel very competent in reviewing literature and determining 
quality of studies. It was valuable to see how to tailor database searches to obtain the best results for 
research. I learned an entirely new skill in using a computer program where I had to learn how to 
program code. This part was the most challenging part of this process as it was like learning a new 
language. However, now I can use this program in future research. This project allowed me to explore 
my own research and own every step of the process. Moving forward I feel confident in my ability to 
conduct research of my own design.  
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